PHIV-infected children and youth have evolved from basic survival to long-term morbidity from the infection and its treatment, potential life-years lost, psychosocial trauma given the loss of parents and caretakers, mental health (eg, depression, post-traumatic stress disorder), cognitive limitations with impaired ability to complete education and develop life skills, managing HIV disclosure, secondary transmission (horizontal and vertical), reproductive issues, and effective transition to adult care services [2, [5] [6] [7] .
Given the longstanding infection of many of these children, waning adherence due to medication fatigue can severely hamper durable virologic suppression and immunologic outcomes [8, 9] . Furthermore, the normal cognitive (eg, concrete thinking, decreased risk perception), developmental (eg, puberty, physiologic changes), and psychosocial changes (eg, decreased parental supervision, sexual identity exploration, peer pressure) that are critical to development of adult behavior [10] can also pose challenges for PHIV-infected youth. The cumulative effect can be lowered adherence to appointments and medications, potentially leading to viremia and immunologic decline [11] .
Rutstein et al [12] previously reported the immunologic and virologic profiles of 263 ART-treated children age 17 years and younger at pediatric sites in the HIV Research Network (HIVRN) during 2001. Only 34 percent of the children had plasma virologic suppression of <400 copies/ mL; the majority of patients had persistent viremia (>400 and <15 000 copies/mL) despite treatment. Given that persistent viremia is associated with immunologic decline, combined with the potential social and cognitive challenges of the adolescent and young adult years, we hypothesized that PHIV-infected children would develop advanced immunosuppression and viremia as they entered adolescence and young adulthood.
In this study, we examine this hypothesis in a cohort of PHIV-infected adolescents and young adults in the HIVRN. We assess changes in advanced immunosuppression and detectable viremia over time. As PHIV-infected youth age, medication fatigue and an increasing sense of autonomy could lower adherence, leading to higher levels of viremia and advanced immunosuppression (an aging effect). Alternatively, advances in ART could increase tolerability and improve adherence, leading to lower levels of viremia and advanced immunosuppression (a time period effect).
METHODS

Study Setting and Participants
This was a retrospective study of 521 PHIV-infected youth enrolled in HIVRN clinics and followed between 2002 and 2010. The HIVRN is a consortium of 18 highvolume US clinic sites (12 adult, 6 pediatric) that provide primary and subspecialty care to HIV-infected children, youth, and adult patients [13, 14] . Two sites had no PHIV-infected patients in the eligible age range. The remaining 16 sites, 6 pediatric and 10 adult, that contributed patients to this analysis varied geographically: Northeast (5), Southern (5), West (5), Midwest (1). Sites annually abstracted specified data elements from patients' medical records; abstracted data were assembled into a uniform database, as previously described [13] . Adolescents and young adults were followed at pediatric or adult sites, because there were no adolescent-only sites included in the network. The study was approved by the Johns Hopkins Institutional Review Board (IRB) and IRBs at each participating institution.
Patients were included if they were PHIV-infected, were 12 years old or older, and were in care, defined as having at least 1 CD4 value and 1 outpatient visit within any given calendar year between the years 2002 and 2010. Patients were excluded if they acquired HIV through blood transfusion, risky behaviors (ie, sexual acquisition or injection drug use), or if the mode of acquisition was unknown, to avoid inclusion of behaviorally infected youth, because these patients may be in the early stages of infection and have different clinical trajectories than PHIV-infected youth [8, 9] . Patients entered (and left) the sample at different points in time; thus, there is both continuity and change in the sample from year to year.
Data Collection and Measures
The 2 dichotomous outcomes of interest were advanced immunosuppression, defined as a CD4 count below 200 cells/mm 3 , and detectable viremia, defined as a viral load 2.6 log 10 HIV-1 RNA copies/mL. Not all individuals had ultrasensitive virologic testing (<1.70 log 10 HIV-1 RNA copies/mL). The first available CD4+ T cell count and the first reported HIV-1 RNA test of each calendar year were used. For descriptive analyses, CD4 was categorized as <200, 200-349, 350-499, and 500 cells/mm 3 .
Demographic and clinical data were collected from the clinical database. Race/ethnicity was based on selfreported data recorded in the medical record and classified as White, Black, Hispanic, and other. The number of outpatient clinic or office visits was determined for each calendar year and categorized as <4 or 4 HIV provider visits per year, based on contemporary Department of Health and Human Services' recommendations for quarterly clinical follow-up [8, 9] . Outpatient clinic visits were limited to visits with an HIV healthcare provider, excluding emergency department administrative, laboratory testing, nurse-only, or psychiatry visits. Clinical site was classified as adult or pediatric. Mental health and substance abuse data were incomplete and therefore not evaluated. Insurance was categorized as insured ( private insurance, Medicaid, Medicare, Dual insurance with Medicaid/Medicare) versus Uninsured/Ryan White/Other (eg, Veteran's administration, county health program). Antiretroviral therapy was defined as concomitant prescription of 3 antiretroviral drugs from at least 2 classes, including acceptable triple nucleoside reversetranscriptase inhibitor regimens, specifically AZT, 3TC, and ABC [8, 9] . Adherence was not assessed because it is not reliably recorded in medical records.
Statistical Analysis
Descriptive statistics were used to assess the demographic (eg, age, sex, race) and clinical (eg, CD4+ T cell counts, HIV-1 RNA, ART prescription, treatment site) characteristics for the cohort. Multivariable logistic regression was used to assess demographic and clinical factors associated with each outcome. Independent variables included age, race or ethnicity, sex, insurance (insured vs uninsured), HIV provider outpatient visits (<4 vs 4 visits), and clinical site of HIV care (adult vs pediatric). Analyses of advanced immunosuppression also included viral load category (<2.6, 2.6-<4.0, >4.0-< 4.7, 4.7-<5.0, and >5.0 log 10 HIV-1 RNA copies/mL). HIV acquisition risk was not included in the analysis because all youth in this cohort were perinatally infected.
The unit of analysis is the person-year. Age and calendar year were treated as time-varying covariates, as was viral load category. Analyses were limited to years in which a patient was in care, defined as having at least 1 outpatient visit and 1 CD4 test recorded in that year. For each patient, data from multiple study years are not independent; therefore, we used generalized estimating equations, with each patient as a cluster and robust standard errors, to deal with the correlation across years for those patients who were in care in multiple study years. Data were analyzed using STATA 11.0 (Stata Corp., College Station, TX). 
Factors Associated With Detectable Viremia
In univariate analysis (Table 2) , factors associated with a higher likelihood of detectable plasma viremia included Hispanic race and treatment at an adult HIV clinical site; ART prescription and more recent year of analysis were associated with a lower likelihood of detectable viremia. In multivariate analysis, a higher likelihood of detectable plasma viremia was significantly associated with older age, Black race, and Hispanic ethnicity. In contrast, ART prescription and more recent year of evaluation were associated with a lower likelihood of detectable plasma viremia. In a sensitivity analysis of only those patientyears in which ART was prescribed (n = 1849), the same factors were associated with detectable viremia (data not shown).
Factors Associated With Advanced Immunosuppression
In univariate analysis (Table 3) , factors associated with a higher likelihood of advanced immunosuppression included older age, higher viral load, and receiving care at an adult HIV clinical site. In multivariate analysis, a higher likelihood of advanced immunosuppression was significantly associated with higher levels of viremia, older age, attending 4 outpatient HIV provider visits during a calendar year, Black race, and Hispanic ethnicity. In contrast, more recent time periods were associated with In a sensitivity analysis of only those patient-years in which ART was prescribed, the same factors were associated with advanced immunosuppression (data not shown).
Consistency Over Time
We assessed whether the same PHIV-infected individuals were severely immunosuppressed in different years. The median number of years with undetectable HIV-1 RNA was 2; the median proportion of years with undetectable HIV-1 RNA was 0.5 years. Although 24% never showed virologic suppression, 29% showed virologic suppression in all years in care. Consistency of severe immunosuppression was greater than for virologic suppression. Overall, 78% of PHIV-infected youth never had a year in which they were severely immunosuppressed, whereas 7% were severely immunosuppressed in all years in care.
DISCUSSION
This study of 521 patients represents one of the larger cohorts of PHIV-infected youth reported to date [15] [16] [17] . We examined 2 time scales: the age of the patient and the calendar year. The effects of the time scales were different. As patients grew older, they were more likely to have advanced immunosuppression and detectable viremia. For both outcomes, the probability rose notably at ages 15-19 and older. In contrast, in more recent calendar years, PHIV-infected youth were less likely to have advanced immunosuppression and detectable viremia.
Overall, the calendar year ( period) effects had a greater impact than aging effects, as suggested by decreasing rates of detectable viremia and advanced immunosuppression over time. Between 2002 and 2010, the number of PHIV-infected youth in the HIVRN cohort increased, likely due to longer survival from a combination of earlier diagnosis, OI prophylaxis, and advances in ART [2, 17] . Since the advent of ART, the mortality for pediatric HIV has declined 9-fold [18] . Although HIV-infected children still have a markedly higher likelihood of death compared with uninfected children, the disease has been transformed into a chronic illness [18] .
The increasing age of the HIVRN PHIV-infected cohort is consistent with other domestic cohorts, including the Pediatric HIV/AIDS Cohort Study (PHACS) [17] . Perinatally human immunodeficiency virus-infected children are now emerging into adolescence and young adulthood, a period of rapid physical growth, cognitive development, and psychosocial evolution [10, [19] [20] [21] . The attempt to balance normal developmental and psychosocial stage with the challenges of living with HIV infection creates the perfect storm for decreased adherence to medications and medical care. This can, in turn, contribute to viremia and immunologic deterioration. In general, PHIV-infected youth had less advanced immunosuppression in more recent years, with increasing proportions having CD4 counts above 200 cells/mm 3 , painting a promising picture of an aging, yet healthier population of PHIV-infected youth. However, the countervailing associations between older age and greater risk of having advanced immunosuppression and detectable viremia are consistent with recent analyses showing that older PHIV-infected patients account for the largest component of the hospitalizations and healthcare costs for pediatric HIV patients [22, 23] .
Over the study period, an increasing proportion (67.4%-84.1%) of PHIV-infected youth were prescribed ART. The increase likely reflects the greater sensitivity of providers to the inflammatory consequences of ongoing viral replication and a growing consensus for earlier ART initiation and maintenance [8, 24] . In addition, increased ART use may be due to the availability of more agents to use in often highly treatment experienced PHIV-infected youth, many of whom have significant resistance due to prior suboptimal ART and nonadherence. Because data on resistance or adherence were not available, we cannot specifically examine these factors.
An increasing proportion of PHIV-infected youth had virologic suppression on their ART regimens over the study period, increasing from 35.5% to 63.0%. This finding is similar to data from PHACS-Adolescent Master Protocol, in which 68% of patients born between [17] . The rate of virologic suppression in recent years for both of these studies is significantly higher than the 34% reported in 2001 for younger PHIV-infected patients (17 years old) in the HIVRN cohort [12] and that of 54.5% recently reported in 2010 for the French Perinatal cohort [15] . This trend also likely reflects the availability of newer more potent and palatable regimens, but it may also reflect the fact that fewer PHIV-infected youth are exposed to suboptimal therapies. This is consistent with our finding that younger individuals were less likely to have advanced immunosuppression, the direct result of persistent viremia [21] . Those with 4 or more outpatient visits were more likely than those with fewer to have severe immunosuppression. This association is probably due to providers' more closely monitoring the condition of those with low CD4 counts, rather than a causal impact of utilization on immune status. Removing this variable from the multivariate analysis produced no substantive change in the results. In addition, the causal relationship between ART and the outcome variables is ambiguous: receipt of ART can affect levels of HIV-1 RNA and CD4, but the latter variables can also trigger initiation of ART. However, we believe that the second effect is muted in these data, because most youth had presumably received ART prior to the study period.
Although it is promising that more PHIV-infected youth are on ART, the fact that nearly 20% in 2010 are not on ART is worrisome, given implications for long-term sequelae (eg, immune deterioration and inflammation) and transmission. In addition, although an increasing proportion of PHIV youth are suppressed on ART, the finding that nearly 40% had detectable viremia in 2010 merits concern for transmission of resistant variants [25] . The reasons for these findings are likely multifactorial, including clinical and psychosocial factors (eg, virologic resistance, medication intolerance, and nonadherence). However, there is concern for horizontal [24] and vertical HIV transmission [6] . PHIV-infected youth are sexually active at rates often higher than reported in uninfected cohorts and are engaging in unprotected intercourse, acquiring sexually transmitted infections, and becoming pregnant [5, 6, 26] . Findings from these studies [5, 6, 26] underscore the importance of exploring strategies that minimize pill burden, toxicities and side effects, and utilizing recent generation agents effective in treating multidrug resistance. In addition, because chronic nonadherence is a significant concern for many youth, strategies such as immune-based therapies, vaccines, high barrier to resistance regimens, bridging strategies, novel therapeutics (eg, depot ART), and behavioral interventions (eg, motivational interviewing, technology and reward-based interventions, education) should be explored [27] [28] [29] [30] [31] .
Many PHIV-infected youth are followed at the same pediatric clinical site from birth. The pediatric clinical team serves not only as the medical team but also as significant members of the youth's social support network, often in lieu of family members who may not be present due to illness, substance abuse, death, etc [32, 33] . Transitioning to adult care is a time of major turmoil for youth with chronic illnesses (eg, congenital heart disease, cystic fibrosis, sickle cell, juvenile-onset diabetes) as well as HIV [34] [35] [36] . Disruption in the social support provided by the pediatric clinical team may adversely impact the youth's mental health and functioning (eg, depression, decreased self-efficacy) [11, 37, 38] , precipitating nonadherence, with resultant viremia and immune deterioration in the case of PHIV infection [7, 39, 40] . Evaluating and implementing effective transition models is critical to supporting PHIV youth through this challenging period [41] . One proposed model is to institute an individualized transition program, where the PHIV-infected youth are maintained at pediatric sites until they have attained specific milestones of medical and health literacy, as well as psychosocial readiness, before transitioning to adult care [7] . Virologic and immunologic outcomes of PHIV-infected youth transitioning to adult clinical sites are an important outcome for future analyses.
Our study is strengthened in that we evaluated PHIV-infected patients being followed at HIV clinical sites under non-trial-based conditions. Regarding study limitations, the data record ART prescription, but we cannot state that ART was taken. We postulated that variations in adherence affect the likelihood of viremia and advanced immunosuppression, but we have no direct evidence of nonadherence beyond viremia, which could be due to nonadherence or resistance and inappropriate regimens. We also do not know why eligible patients were not prescribed ART, specifically, whether it was the patient's or provider's decision. We do not have data on socioeconomic status, mental health, substance abuse, sexuality, and other psychosocial variables that may be important in explaining some of our findings. Finally, clinical sites volunteered to participate in HIVRN, and the resulting sample may not be representative of the full population of PHIV-infected youth in treatment.
CONCLUSIONS
Over time, more PHIV-infected youth are achieving virologic control on ART and fewer are entering adolescence and young adulthood with advanced immunosuppression, based on the results from the study sites. However, older and minority youth are at particularly increased risk of advanced immunosuppression and detectable viremia. Of concern is that one third of treated PHIV-infected youth have viremia, with likely resultant inflammation, immune deterioration, and potential for secondary transmission. Studies that evaluate the impact of critical psychosocial parameters (eg, mental health, substance abuse, self-efficacy) on clinical outcomes are important to designing and implementing new strategies to minimize viremia and immunosuppression and maximize long-term disease and comorbidity-free survival for PHIV-infected youth.
